Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAINIER: Simtuzumab (GS-6624) in Idiopathic Pulmonary Fibrosis
2012-001571-36Phase 2Terminated
- Sponsor
- Gilead Sciences
- Start
- Feb 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing Simtuzumab with Placebo (2 arms). Primary endpoint: All-cause mortality. Started Feb 2013; status: terminated.
02
Drugs
simtuzumab
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2012-001571-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001571-36.